Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546002 | 0.85 | KCNH2 (0.47) | KCNH2DPP4SSTR2MTOR | |
| SCHEMBL3551596 | 0.85 | KCNH2 (0.60) | KCNH2DPP4SSTR2MTOR | |
| SCHEMBL3552603 | 0.85 | KCNH2 (0.60) | KCNH2DPP4SSTR2MTOR | |
| SCHEMBL3550302 | 0.85 | KCNH2 (0.60) | KCNH2DPP4SSTR2MTOR | |
| SCHEMBL2822985 | 0.84 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL3144572 | 0.84 | KDM1A (0.36) | KCNH2DPP4HRH2HRH1HRH3 | |
| SCHEMBL2930163 | 0.81 | KCNH2 (0.58) | KCNH2SSTR2MTOR | |
| SCHEMBL2768192 | 0.77 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL3546754 | 0.77 | KCNH2 (0.41) | KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL3547756 | 0.76 | KCNH2 (0.41) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | AADAC, AZI2, NNMT | KCNH2 2592/4885DPP4 652/4885DPP8 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.